Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
0 competitors in Chemotherapy-induced Nausea and Vomiting
View Full LandscapeTarget Indication
Chemotherapy-induced Nausea and Vomiting
Clinical Trial
NCT01697579Last updated: 12/19/2025
No patent data available. Pre-approval drugs may not have Orange Book listings.
Ivemend
Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and paediatric patients aged 6 months and older. Ivemend 150 mg is given as part of a combination therapy.
View on EMA